Xiangyu Medical Co.,Ltd (SHA:688626)
China
· Delayed Price · Currency is CNY 64.41
+0.43 (0.67%)
Mar 9, 2026, 3:00 PM CST
Xiangyu Medical Co.,Ltd Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Operating Revenue | 767.75 | 733.63 | 736.61 | 483.87 | 515.8 | Upgrade
|
| Other Revenue | - | 9.9 | 8.2 | 4.66 | 7.7 | Upgrade
|
| Revenue | 767.75 | 743.53 | 744.81 | 488.53 | 523.5 | Upgrade
|
| Revenue Growth (YoY) | 3.26% | -0.17% | 52.46% | -6.68% | 5.65% | Upgrade
|
| Cost of Revenue | - | 252.61 | 243.35 | 170.08 | 169.57 | Upgrade
|
| Gross Profit | 767.75 | 490.92 | 501.46 | 318.44 | 353.92 | Upgrade
|
| Selling, General & Admin | - | 274.02 | 210.41 | 175.89 | 140.42 | Upgrade
|
| Research & Development | - | 152.02 | 106.75 | 92.41 | 68.61 | Upgrade
|
| Other Operating Expenses | 690.68 | -7.41 | -9 | -3.6 | 0.55 | Upgrade
|
| Operating Expenses | 690.68 | 421.82 | 310.31 | 264.77 | 211.78 | Upgrade
|
| Operating Income | 77.07 | 69.09 | 191.15 | 53.67 | 142.15 | Upgrade
|
| Interest Expense | - | -3.63 | -2.66 | -0.19 | - | Upgrade
|
| Interest & Investment Income | - | 26.6 | 38.82 | 37.59 | 33.73 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.07 | 0.02 | 0.02 | -0.02 | Upgrade
|
| Other Non Operating Income (Expenses) | -2.28 | 1.04 | 2.39 | 2.61 | 2.16 | Upgrade
|
| EBT Excluding Unusual Items | 74.79 | 93.17 | 229.72 | 93.7 | 178.02 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -3.24 | -1.06 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.07 | 0.01 | - | -0.01 | Upgrade
|
| Asset Writedown | - | -0.05 | -0.02 | -0.25 | - | Upgrade
|
| Other Unusual Items | - | 14.04 | 17.55 | 40.6 | 44.72 | Upgrade
|
| Pretax Income | 74.79 | 107.24 | 244.03 | 132.99 | 222.72 | Upgrade
|
| Income Tax Expense | -3.91 | 4.38 | 15.72 | 9.7 | 23.18 | Upgrade
|
| Earnings From Continuing Operations | 78.7 | 102.85 | 228.31 | 123.3 | 199.54 | Upgrade
|
| Minority Interest in Earnings | - | 0.09 | -1.17 | 2.17 | 2.36 | Upgrade
|
| Net Income | 78.7 | 102.94 | 227.14 | 125.47 | 201.9 | Upgrade
|
| Net Income to Common | 78.7 | 102.94 | 227.14 | 125.47 | 201.9 | Upgrade
|
| Net Income Growth | -23.55% | -54.68% | 81.03% | -37.85% | 2.87% | Upgrade
|
| Shares Outstanding (Basic) | 154 | 156 | 158 | 159 | 150 | Upgrade
|
| Shares Outstanding (Diluted) | 154 | 156 | 158 | 159 | 150 | Upgrade
|
| Shares Change (YoY) | -1.07% | -1.12% | -0.68% | 6.20% | 24.97% | Upgrade
|
| EPS (Basic) | 0.51 | 0.66 | 1.44 | 0.79 | 1.35 | Upgrade
|
| EPS (Diluted) | 0.51 | 0.66 | 1.44 | 0.79 | 1.35 | Upgrade
|
| EPS Growth | -22.73% | -54.17% | 82.28% | -41.48% | -17.68% | Upgrade
|
| Free Cash Flow | - | -260.3 | -251.35 | -16.37 | 31.97 | Upgrade
|
| Free Cash Flow Per Share | - | -1.67 | -1.59 | -0.10 | 0.21 | Upgrade
|
| Dividend Per Share | - | 0.240 | 0.530 | 0.240 | 0.380 | Upgrade
|
| Dividend Growth | - | -54.73% | 120.90% | -36.84% | 2.70% | Upgrade
|
| Gross Margin | 100.00% | 66.03% | 67.33% | 65.18% | 67.61% | Upgrade
|
| Operating Margin | 10.04% | 9.29% | 25.66% | 10.99% | 27.15% | Upgrade
|
| Profit Margin | 10.25% | 13.84% | 30.50% | 25.68% | 38.57% | Upgrade
|
| Free Cash Flow Margin | - | -35.01% | -33.75% | -3.35% | 6.11% | Upgrade
|
| EBITDA | 113.15 | 105.17 | 208.57 | 69.74 | 153.52 | Upgrade
|
| EBITDA Margin | 14.74% | 14.14% | 28.00% | 14.27% | 29.33% | Upgrade
|
| D&A For EBITDA | 36.08 | 36.08 | 17.41 | 16.06 | 11.37 | Upgrade
|
| EBIT | 77.07 | 69.09 | 191.15 | 53.67 | 142.15 | Upgrade
|
| EBIT Margin | 10.04% | 9.29% | 25.66% | 10.99% | 27.15% | Upgrade
|
| Effective Tax Rate | - | 4.09% | 6.44% | 7.29% | 10.41% | Upgrade
|
| Revenue as Reported | - | 743.53 | 744.81 | 488.53 | 523.5 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.